PT490 – Dr. Robin Carhart-Harris – Plasticity, the Role of Set and Setting, and the Influence of Psychedelics
Listen now
Description
In this episode, Joe interviews Dr. Robin Carhart-Harris: founder and head of the Centre for Psychedelic Research at Imperial College London, founding director of the Neuroscape Psychedelics Division at University of California, San Francisco (UCSF), and founder of the Carhart-Harris Lab. A legendary researcher, he talks about his psychedelic origins: studying Freud, Jung, and eventually Stan Grof and depth psychology to try and better understand the unconscious. He discusses the growth of psychedelics and the cultural shifts he’s noticed (especially in the U.S.), as well as what he’s working on today: researching the influence of psychedelics on set and setting by studying experiences in both enriched and unenriched environments. He also talks about: Plasticity: how he defines it, how it relates to critical reopening periods, and how it’s a fundamental thing that transcends the metrics we use to measure it Early LSD studies, the nervousness surrounding he and David Nutt dosing Ben Sessa, and the youthful energy that kept them going How plasticity could be exploited to help relieve chronic pain The potential of psychedelics to help with fibromyalgia and anorexia How psychedelic-assisted therapy brought care back to health care and more! UCSF is seeking survey volunteers, so if you’ve had more than three experiences with ketamine, MDMA, and psilocybin (must have experiences with all three) and want to contribute, do so here. Click here to head to the show notes page. 
More Episodes
Psychedelics in palliative care has become an exciting new framework for people looking to ease anxiety and embrace spirituality, but the concept is not as simple as just providing a substance. In this episode, Joe interviews Livi Joy: Director of Health and Safety, Existential Palliative...
Published 07/26/24
Published 07/26/24
In this episode, Joe interviews Erica Rex, MA: award-winning journalist, past guest, thought leader on psychedelic medicine, and participant in one of the first clinical trials using psilocybin to treat cancer-related depression. She tells the story of her recent harrowing experience, brought on...
Published 07/23/24